<DOC>
	<DOC>NCT00707408</DOC>
	<brief_summary>This is a multicenter open-label phase II trial of high dose imatinib mesylate in patients with AML in first or second relapse, or with refractory disease. Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Response is assessed after 1, 2 and 3 months of treatment by bone marrow aspirate.</brief_summary>
	<brief_title>High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)</brief_title>
	<detailed_description>Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.</detailed_description>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>age &gt; 18 years, AML in first or second relapse, refractory AML performance status of 02 on the Eastern Cooperative Oncology Group scale, adequate hepatic and renal functions (AST or ALT &lt;= 5 times the upper limit of normal creatinine &lt; 2 times the upper limit of normal) 20% blasts in bone marrow, 70% of bone marrow blast population ckit positive as assessed by immunophenotyping BcrAbl negative chromosomal analysis (assessed by fluorescence in situ hybridization; FISH), and no chromosome 512 translocation Previous treatment by Imatinib Secondary AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>